Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study.

Key Points

• Dementia outcomes improved among patients using tirzepatide and semaglutide, lowering risks overall.
• The analysis was conducted on a significant cohort of individuals with type 2 diabetes, emphasizing real-world effectiveness.
• This retrospective cohort study evaluated the effects of sglt2-inhibitors on dementia alongside tirzepatide and semaglutide use.
• Findings suggest a potential linkage between diabetes management and reduced dementia occurrence, calling for further research.